Back to discover
Drug

Magnesium sulfate

Approved · FDA
Emerging researchLate-stage developmentRising momentum
Also known as Concept OB, Eldertonic, Ellis Tonic, Ferrocite Plus+17 more

Concept OB, Eldertonic, Ellis Tonic, Ferrocite Plus, Hemocyte Plus, Mg SO4, MgSO4, Sutab, Tandem OB, Tis-U-Sol, MAGNESIUM (AS SULFATE), MAGNESIUM SULFATE, UNSPECIFIED, MAGNESIUM SULFATE, UNSPECIFIED FORM, Magnesium Sulfate Anhydrous, Magnesium Sulfate, Injectable, Magnesium Sulfate/Potassium Sulfate/Sodium Sulfate, Magnesium sulfate (1:1), Magnesium sulphate, Magnesiumsulfat, Mg sulfate, magnesium(II) sulfate.

4
Research papers
26
Active clinical trials
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Biomarkers in Management of PP Preeclampsia

Clinical trial2026-06-01Results expected Q2 2027 · ClinicalTrials.gov

Magnesium Sulfate in Bronchial Asthma and Acute Bronchiolitis in Children

Clinical trial2026-05-01Primary completion · ClinicalTrials.gov

Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

Research2010-12-28Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Magnesium sulfate
Aliases & brands
Concept OBEldertonicEllis TonicFerrocite PlusHemocyte PlusMg SO4MgSO4SutabTandem OBTis-U-SolMAGNESIUM (AS SULFATE)MAGNESIUM SULFATE, UNSPECIFIEDMAGNESIUM SULFATE, UNSPECIFIED FORMMagnesium Sulfate AnhydrousMagnesium Sulfate, InjectableMagnesium Sulfate/Potassium Sulfate/Sodium SulfateMagnesium sulfate (1:1)Magnesium sulphateMagnesiumsulfatMg sulfatemagnesium(II) sulfate
RxNorm CUI
6585
ChEMBL ID
CHEMBL2021423
UNII
ML30MJ2U7I
Regulatory jurisdictions
mhrafda

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2026-07-09
Latest approval
2026-07-09
Authorities
FDA · MHRA
Total events
2
fdaU.S. Food and Drug Administration· 1 event
2026-07-09Approval
Approval: MAGNESIUM SULFATE (ANDA217461)
Evidence ↗
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2019-05-17Safety communicationSafety
Drug Safety Update: Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

197 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
197
registered trials across all phases
LATEST COMPLETION 2026
26
Active studies
24
Recruiting
157
Late-stage (III+)
114
Completed
57
Discontinued
PHASE DISTRIBUTIONn = 197
Early Phase 14Phase 15Phase 1 / 29Phase 222Phase 2 / 317Phase 329Phase 451Phase N / A60

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20072017
Most influential
Recent papers
Major research themes1
Arthroscopy1
Journals, researchers & institutions
Top journals
  • Acta orthopaedica et traumatologica turcica1
  • Advanced biomedical research1
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
  • Obstetrics and gynecology1
Leading researchers
  • Alberts SR1
  • Altıntaş F1
  • Burrs D1
  • Campbell L1
  • Caughey AB1
  • Ching S1
  • Chitaley U1
  • Chitkara U1
Leading institutions
free-text, unnormalised
  • Mayo Clinic Rochester1
  • School of Medicine1
  • Stanford University Medical Center1
  • Yeditepe University Faculty of Medicine1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.